Market Overview:
Adoptive cell therapy involves isolation of a patient’s own immune cells such as T cells, natural killer (NK) cells, antigen-specific T cells, genetically engineered T cells, tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer cells. These isolated cells are then modified or activated ex vivo and re-administered to the patient to induce antitumor immune responses. Adoptive cell therapy is widely used in the treatment of cancer indications such as melanoma, lymphoma, multiple myeloma, and lung cancer.
Market Dynamics:
Rise in demand for personalized medicine is expected to drive growth of the adoptive cell therapy market over the forecast period. Personalized medicine relies on an individual’s genetic profile to guide decisions made in regard to prevention, diagnosis, and treatment of diseases. Adoptive cell therapy is an important part of personalized medicine as it involves isolation of patient’s own immune cells which are then modified accordingly to induce antitumor responses. Furthermore, advancements in cell therapy technologies such as CAR T-cell therapy are also expected to fuel market growth between 2022 and 2030. CAR T-cell therapy involves genetically engineering a patient’s own T cells to express chimeric antigen receptors (CARs) that specifically target tumor antigens present on cancer cells. Growing adoption of CAR T-cell therapy in treating various cancer indications worldwide is expected to propel the adoptive cell therapy market growth.
Segment Analysis
The global Adoptive Cell Therapy Market Demand is segmented into cancer and non-cancer. The cancer segment dominates the market owing to large patient pool suffering from cancer across the globe. The segment accounted for over 70% market share in 2022 due to increasing prevalence of hematologic malignancies and solid tumors.
PEST Analysis
Political: The governments across the globe are developing supportive policies and reimbursement programs to promote research in cell and gene therapy which is positively impacting the market growth.
Economic: The rising healthcare spending to treat cancer and other chronic diseases is fueling the demand for adoptive cell therapies.
Social: Increasing awareness about advanced cell therapy treatments and rising adoption of personalized medicine are driving the market.
Technological: Significant investments in research and development of novel platforms for cell production, gene editing tools, and development of mechanism to produce high quality cell products at large scale are expanding technological capabilities.
Key Takeaways
The global adoptive cell therapy market is expected to witness high growth, exhibiting CAGR of 21.5% over the forecast period, due to increasing prevalence of cancer cases globally. The market was valued at US$ 4,932.5 million in 2023.
Regional analysis
North America dominated the global market in 2022 owing to presence of major players in the US and developed healthcare infrastructure. However, Asia Pacific is expected to be the fastest growing market due to rising cancer incidence, healthcare infrastructure development and fast approval processes.
Key players
Key players operating in the adoptive cell therapy market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs. Novartis dominates the market due to its robust portfolio of CAR T-cell therapies.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
